Clinical trial NCT06565988: A Post-market-clinical Follow-up Investigation of Safety and Performance by Decoria® Voluma
Official title: A Post-market-clinical Follow-up Investigation of Safety and Performance of Decoria® Voluma
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Midface Volume Deficit
Keywords: tissue augmentation
Lead sponsor: Bohus Biotech AB
Sponsor class: INDUSTRY
Collaborators: name: Key2Compliance
First posted: 2024-08-22
Enrollment: 125
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A post-market-clinical follow-up investigation of safety and performance of Decoria® Voluma by the correction of midface volume deficit by tissue augmentation in cheek region.

Detailed description: This will be a post-market, open-label, prospective, interventional, confirmatory, evaluator-blinded, multi- centre, clinical investigation to confirm the clinical safety and performance profile of Decoria® Voluma for the correction of midface volume deficit by tissue augmentation in cheek region.

Subjects desiring correction of cheek volume at the participating sites will be asked to participate in the clinical investigation. According to the national legislation, all subjects must have a consultation with the respective clinic and receive both oral and written information at least 48 hours prior to treatment with fillers, as to allow for sufficient reflection time.

If the subject decides to participate, the subject will receive treatment on Day 0 (Visit 1). At 1 month visit (Visit 2) an optional touch-up may be given as well as assessments performed. All subjects will be followed for 6 months with follow-up and assessments either by physical visits to a clinic (Visit 2 and Visit 4) or by phone call (Visit 3).

A total of 4 visits (including screening Visit 0) at the site are planned for each subject.

Standardized facial photography will be taken prior to and after treatment during Visit 1 and during each follow-up visit at the clinic (Visit 2 and 4), for evaluation according to GAIS grading and for the exploratory instrumental evaluation of cheek volume. GAIS will be used for blinded investigator assessment, treating investigator assessment and patient satisfaction.

Numeric Pain Rating Scale (NRS) at each visit involving an injection (Visit 1 and Visit 2- optional touch up) will be used to measure pain.

Eligibility criteria: Inclusion Criteria:

1. Adults ≥18 years, males and females.
2. Able and willing to give written informed consent for participation in the investigation.
3. Treating investigator considers the subject's cheeks amenable to an improvement of at least 1 grade on the GAIS. At least one side of face should either have a potential to enhance cheek volume or have moderate to severe cheek volume deficit. The grades do not have to be the same on both sides.
4. Ability to follow study instructions and likely to complete all required visits.

Exclusion Criteria:

1. Pregnant or lactating females.
2. Any previous hypersensitivity reaction to any constituent of the Investigational medical device (IMD) or to local anaesthetic products.
3. Any corrective procedures performed or planned in the midface region (e.g., silicone implants, permanent fillers, absorbable and non-absorbable sutures, laser therapy, dermabrasion, dental implants) that may confound the evaluation of safety and performance of the IMD.
4. Any other intradermal injection, such as semi-permanent fillers or botulinum toxin (no complications are allowed), received in the same injection area within 12 months of the Treatment visit (Visit 1) that may confound the evaluation of safety and performance of the IMD.
5. Has an ongoing episode/relapse, recently diagnosed or newly started medication of an autoimmune disease, as judged by the investigator.
6. Has any chronic or acute skin disease or inflammation (such as pimples, rashes or hives) within or close to the treatment area.
7. Has any treatments (thrombolytics, anticoagulants) or disease related to the coagulation system.
8. Subjects that have taken any type of vaccine within two weeks prior injection with the IMD.
9. Patients receiving interferon and ribavirin treatment.
10. Features that may interfere with the visual assessment such as recent cosmetic treatment,scarring, abscess, piercing or tattoo.
11. Participation in a clinical investigation that may affect the safety or performance of this investigation, as judged by the Principal Investigator, or authorized designee.
12. Employees of the study site or the sponsor directly involved with the conduct of the investigation.

Primary outcomes:
measure: Primary efficacy endpoint
timeFrame: From pre-intervention baseline, to 6 months post-treatment
measure: Primary safety endpoint
timeFrame: Baseline to end of study (6 months)
Secondary outcomes:
measure: Secondary endpoint
timeFrame: Baseline (visit 1) and (visit 2) (30 days post baseline)
measure: Secondary endpoint
timeFrame: 30 days and 180 days post treatment
measure: Secondary endpoint
timeFrame: 30 days and 180 days post treatment
measure: Secondary endpoint
timeFrame: Baseline (visit 1) and (visit 2) (30 days post baseline)
measure: Secondary endpoint
timeFrame: Baseline, 30 days and 180 days post treatment
Other outcomes:
Locations:
city: Göteborg
country: Sweden
facility: Inskinity
city: Göteborg
country: Sweden
facility: Göteborgs Laser & Estetik
city: Karlstad
country: Sweden
facility: Svenska Hudkliniker
city: Stockholm
country: Sweden
facility: Inskinity
city: Stockholm
country: Sweden
facility: Florakliniken
city: Stockholm
country: Sweden
facility: The Faculty
city: Stockholm
country: Sweden
facility: Svenska Hudkliniker
Study officials:
affiliation: Florakliniken, Stockholm, Sweden
name: Lucian Grema, M.D
role: PRINCIPAL_INVESTIGATOR
References: